NCT03226522Phase 2, phase 3Completed

Addressing Dementia Via Agitation-Centered Evaluation

Study sponsor: Axsome Therapeutics, Inc. · AXSM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-04-17Actual
Enrollment · participants366Actual
Source updated2023-09-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.